uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipel... uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. 詳細を表示
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.55 | -20.2279202279 | 17.55 | 19.18 | 13.85 | 1604572 | 16.86111193 | CS |
4 | -0.98 | -6.54205607477 | 14.98 | 19.18 | 13.85 | 1583084 | 16.82859548 | CS |
12 | 7.72 | 122.929936306 | 6.28 | 19.18 | 5.35 | 2244594 | 13.61107324 | CS |
26 | 7.35 | 110.526315789 | 6.65 | 19.18 | 4.45 | 2076046 | 11.00952262 | CS |
52 | 7.38 | 111.480362538 | 6.62 | 19.18 | 3.73 | 1663486 | 9.10278229 | CS |
156 | -5.39 | -27.797833935 | 19.39 | 28.255 | 3.73 | 1073668 | 11.78194387 | CS |
260 | -60.22 | -81.1371597952 | 74.22 | 76.6869 | 3.73 | 842926 | 18.49194424 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約